Are the true impacts of adverse events considered in economic models of antineoplastic drugs? A systematic review.

about

Are the true impacts of adverse events considered in economic models of antineoplastic drugs? A systematic review.

Item

http://www.wikidata.org/entity/Q38152967

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

Are the true impacts of advers ...... ic drugs? A systematic review.

@en

type

Item

label

Are the true impacts of advers ...... ic drugs? A systematic review.

@en

prefLabel

Are the true impacts of advers ...... ic drugs? A systematic review.

@en

P1476

Are the true impacts of advers ...... tic drugs? A systematic review

@en

P2093

Marion Haas

http://www.w3.org/2001/XMLSchema#string

P2860

Medical visits for chemotherapy and chemotherapy-induced neutropenia: a survey of the impact on patient time and activities

Cetuximab for the treatment of colorectal cancer.

Pharmacoeconomic analysis of oprelvekin (recombinant human interleukin-11) for secondary prophylaxis of thrombocytopenia in solid tumor patients receiving chemotherapy

Dose-response effect of adjuvant chemotherapy in breast cancer

Cost data for individual patients included in clinical studies: no amount of statistical analysis can compensate for inadequate costing methods.

Evaluating the total costs of chemotherapy-induced toxicity: results from a pilot study with ovarian cancer patients.

Economic burden of haematological adverse effects in cancer patients: a systematic review.

Balancing the benefits and costs of colony-stimulating factors: a current perspective.

Topotecan, pegylated liposomal doxorubicin hydrochloride and paclitaxel for second-line or subsequent treatment of advanced ovarian cancer: a systematic review and economic evaluation.

Patient perceptions of the side-effects of chemotherapy: the influence of 5HT3 antagonists.

P2888

s40258-013-0058-5

P304

619-637

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S40258-013-0058-5

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Rosalie Viney

Alison Pearce

P577

2013-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1013764731

http://www.w3.org/2001/XMLSchema#string

P698

24129649

http://www.w3.org/2001/XMLSchema#string